Merck’s Keytruda (pembrolizumab) + CT Receives NMPA’s approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

 Merck’s Keytruda (pembrolizumab) + CT Receives NMPA’s approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

Merck’s Keytruda (pembrolizumab) + CT Receives NMPA’s approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III KEYNOTE-407 study assessing Keytruda + CT (carboplatin and either paclitaxel or nab-paclitaxel) in patients with metastatic sq. NSCLC and data from the extension of the global study in Chinese patients
  • The P-III KEYNOTE-407 study results: improvement in OS and PFS; 36% reduction in risk of death; 44% reduction in risk of progression. Extension study results: 56% reduction in risk of death; improvement in PFS with a 68% reduction in risk of progression
  • KEYTRUDA is an anti-PD-1 therapy, acts by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first approved therapy in combination with CT for 1L treatment of both sq. & non sq. NSCLC in China          

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Oncozine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post